Global Information
회사소개 | 문의 | 위시리스트

세계의 바이러스 결막염 파이프라인 약제 시장(FST-100 및 APD-209) : 업계 분석, 파이프라인 리뷰, 특허 분석 및 향후 예측(2020-2023년)

Viral Conjunctivitis Therapeutics and Pipeline Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027

리서치사 Transparency Market Research
발행일 2019년 07월 17일 발행예정 상품 코드 364443
페이지 정보 영문
가격
US $ 5,795 ₩ 6,889,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 인쇄는 가능하지만, 전체 페이지 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,795 ₩ 10,456,000 PDF by E-mail (5-user license) help
5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 전체 페이지 인쇄는 1명당 1회로 한정하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,795 ₩ 14,023,000 PDF by E-mail (Corporate License) help
기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


세계의 바이러스 결막염 파이프라인 약제 시장(FST-100 및 APD-209) : 업계 분석, 파이프라인 리뷰, 특허 분석 및 향후 예측(2020-2023년) Viral Conjunctivitis Therapeutics and Pipeline Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027
발행일 : 2019년 07월 17일 발행예정 페이지 정보 : 영문

바이러스 결막염 파이프라인 약제 시장에서 영국, 미국, 독일, 호주, 일본, 브라질이 주요 시장이며, 지속중인 임상시험을 고려하면 미국이 향후 몇 년간 시장을 독점할 것으로 예측됩니다. 미국의 바이러스 결막염 파이프라인 약제 시장은 2020-2023년간 46.5%의 연평균 성장률(CAGR)로 성장할 전망입니다.

세계의 바이러스 결막염(Viral Conjunctivitis) 파이프라인 약제 시장을 조사했으며, 시장 현황과 향후 전망, 약제별·국가별 동향, 시장 진출기업 프로파일 등을 정리하여 전해드립니다.

제1장 서론

제2장 주요 요약

제3장 업계 분석

  • 서론
    • 징후와 증상
    • 진단
    • 관리
  • 시장 동향
    • 시장 성장 촉진요인
      • 큰 미충족 요구
      • 강력한 파이프라인
    • 시장 성장 저해요인
      • 낮은 진단률
      • 자가 제한 조건(Self-Limiting Condition)
    • 기회
      • 엄격한 연구개발 활동에 대한 투자
    • 상품화 활동 강화
  • 역학 환경
  • 파이프라인 약제의 특허 분석

제4장 파이프라인 약제별 시장

  • 서론
  • FST-100
  • APD-209
  • 조기 임상시험

제5장 시장 세분화 : 국가별

  • 서론
  • 미국
  • 영국
  • 독일
  • 호주
  • 일본
  • 브라질

제6장 제안

제7장 기업 개요

  • Adenovir Pharma AB
  • Allergan plc
  • NanoViricides, Inc.
  • Shire plc
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • Panoptes Pharma GES.M.B.H.
  • NicOx S.A.

도표

LSH 16.08.04

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Figures

  • FIG. 1: Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
  • FIG. 2: Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
  • FIG. 3: Viral Conjunctivitis: Signs and Symptoms
  • FIG. 4: Market Revenue of FST-100, (US$ Mn), 2020-2023
  • FIG. 5: Market Revenue of APD-209, (US$ Mn), 2021-2023
  • FIG. 6: U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020-2023
  • FIG. 7: U.K. Market Revenue, (US$ Mn), 2021-2023
  • FIG. 8: Germany Market Revenue, (US$ Mn), 2021-2023
  • FIG. 9: Australia Market Revenue, (US$ Mn), 2022-2023
  • FIG. 10: Japan Market Revenue, (US$ Mn), 2022-2023
  • FIG. 11: Brazil Market Revenue, (US$ Mn), 2020-2023
  • FIG. 12: Allergan Financial Overview: (US$ Mn), 2012-2014
  • FIG. 13: NanoViricides, Inc., Financial Overview: (US$ Mn), 2013-2015
  • FIG. 14: Shire plc, Financial Overview: (US$ Mn), 2013-2015
  • FIG. 15: NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013-2015
  • FIG. 16: Novartis AG, Financial Overview: (US$ Mn), 2013-2015
  • FIG. 17: NicOx S.A., Financial Overview: (US$ Mn), 2013-2015

List of Tables

  • TABLE 1: Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
  • TABLE 2: Viral Conjunctivitis: Management
  • TABLE 3: Epidemiology
  • TABLE 4: Patent Analysis of Pipeline Drugs
  • TABLE 5: Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch-2023
  • TABLE 6: Early Stage Preclinical Trials
  • TABLE 7: Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020-2023

Viral conjunctivitis therapeutics is undergoing a transitional phase. Currently, there is no drug available for the treatment of viral conjunctivitis. However, the presence of a robust pipeline indicates towards a thriving future. The global market for viral conjunctivitis pipeline drugs is likely to exhibit a thumping CAGR of 69.60% between 2020 and 2023 and reach an opportunity worth US$462.4 mn by the end of the forecast period.

The increasing investments from ophthalmic drug manufacturers for the development of efficient treatment for viral conjunctivitis, coupled with the increasing awareness among people and augmenting expenditure on healthcare, are accelerating the growth rate of this market significantly.

On the other hand, lower diagnosis rate of viral conjunctivitis is decreasing the patient pool for the treatment, causing major hindrance in the market's growth.

Pipeline Drugs in U.S. Gain Momentum from Promising Results of Ongoing Clinical Trials

The U.K., the U.S., Germany, Australia, Japan, and Brazil are the key regional markets for viral conjunctivitis pipeline drugs. Considering the ongoing clinical trials, the U.S. is likely to occupy the leading position among these in the coming years. The major factors driving the growth in this market are promising results of the ongoing clinical trials, the increasing awareness regarding eye care among patients and medical professionals, the high cost of the drugs, and the availability of viral conjunctivitis diagnostic tests.

The U.S. market for viral conjunctivitis pipeline drugs is projected to report a CAGR of 46.50% during the period from 2020 to 2023.

APD-209 to Exceed FST-100 by 2023

APD-209 and FST-100 are the main viral conjunctivitis drugs in the pipeline. Among the two, FST-100 is projected to hold the largest share in the market by 2020. Foresight Biotherapeutics Inc. initiated the development of FST-100; however, the company was acquired by Shire Plc. in the midway. In May 2014, the drug completed its phase II clinical trial successfully and is expected to enter the phase III of clinical trials in 2016.

Presently, the APD-209 is witnessing moderate rise; however, in the coming years, it will report a higher demand than FST-100. The drug, being developed by Adenovir Pharma AB, is in its second phase of clinical trial. It is likely to enter the third phase by mid-2016.

The market for FST-100 is projected to rise at a CAGR of 27.40% between 2020 and 2023 while the APD-209 market is likely to report a CAGR of 55.0% during the same period.

Leading Players Focus on Research Activities Thanks to Escalating Demand for Targeted Drugs for Viral Conjunctivitis

On the forefront of the global viral conjunctivitis pipeline drugs market are Panoptes Pharma GES.M.B.H., Shire Plc., Allergan Plc, Novartis AG, NovaBay Pharmaceuticals Inc., Adenovir Pharma AB, NicOx S.A., and NanoViricides Inc. As the demand for targeted drugs for viral conjunctivitis is rising, leading enterprises are focusing aggressively on research activities for the development of efficient treatments as well as diagnostic tests for viral conjunctivitis. New entrants in this market are recommended to enhance their distribution networks through strategic partnerships and alliances with local distributors.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Assumptions
  • 1.4. Market Segmentation

2. Executive Summary

  • 2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
  • 2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market - Industry Analysis

  • 3.1. Introduction
    • 3.1.1. Sign and Symptoms
    • 3.1.2. Diagnosis
    • 3.1.3. Management
  • 3.2. Market Dynamics
    • 3.2.1. Market Drivers
      • 3.2.1.1. Large Unmet Needs
      • 3.2.1.2. Strong Pipeline
    • 3.2.2. Restraints
      • 3.2.2.1. Low diagnosis rate
      • 3.2.2.2. Self-Limiting Condition
    • 3.2.3. Opportunity
      • 3.2.3.1. Investment in Rigorous R&D Activities
      • 3.2.3.2. Strengthen Commercialization Activities
  • 3.3. Epidemiology
  • 3.4. Patent Analysis of Pipeline Drugs

4. Market Segmentation - By Pipeline Drug

  • 4.1. Introduction
  • 4.2. Market Revenue of FST-100 (SHP-640), 2020-2023, (US$ Mn)
  • 4.3. Market Revenue of APD-209, 2021-2023, (US$ Mn)
  • 4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation - By Country

  • 5.1. Introduction
  • 5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020-2023, (US$ Mn)
  • 5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021-2023, (US$ Mn)
  • 5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021-2023, (US$ Mn)
  • 5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022-2023, (US$ Mn)
  • 5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022-2023, (US$ Mn)
  • 5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020-2023, (US$ Mn)

6. Recommendations

7. Company Profiles

  • 7.1. Adenovir Pharma AB
  • 7.2. Allergan plc
  • 7.3. NanoViricides, Inc.
  • 7.4. Shire plc
  • 7.5. NovaBay Pharmaceuticals, Inc.
  • 7.6. Novartis AG
  • 7.7. Panoptes Pharma GES.M.B.H.
  • 7.8. NicOx S.A.
Back to Top
전화 문의
F A Q